Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors

NCT06707610 is registered in ClinicalTrials.gov with Shanghai Allink Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT06707610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06707610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ALK202 for Injection in Adult Participants with Advanced Solid Tumors
Lead sponsor
Shanghai Allink Biotherapeutics Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
February 10, 2025
Completion date
December 31, 2028
Enrollment
234 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor